You need Adobe Flash and Javascript to view this file Ny_forside
Prediction of Mild Cognitive Impairment that Evolves into Alzheimer’s Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study
DiaGenic's pilot study demonstrates for the first time that Mild cognitive impairment that evolves into Alzheimer’s Disease dementia within 2 years may be predicted by analyzing gene expression in blood.
Read more about Prediction of Mild Cognitive Impairment that Evolves into Alzheimer’s Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study
Notice to the Oslo Stock Exchange Wed, 05 Jun 2013 08:00:00 +0200
DiaGenic installs state-of-the-art qPCR technology from Life Technologies Corporation
Read moreCalendar
30.05.2013 - 31.05.2013 - Karlstad, Sweden
DiaGenic presents at Swedish dementia conference, 30th and 31st of May - Karlstad, Sweden
DiaGenic’s Chief Medical Officer Magnus Sjögren will present on blood based diagnosis of Alzheimer’s disease at the Swedish dementia conference in Karlstad, Sweden.
Read more about DiaGenic presents at Swedish dementia conference, 30th and 31st of May - Karlstad, Sweden